Swedish Energy Services Stock News

OM:ACAST
OM:ACASTInteractive Media and Services

European Companies Trading Below Estimated Value In April 2026

As European markets continue to digest corporate earnings and geopolitical developments, the pan-European STOXX Europe 600 Index has shown positive momentum, reflecting a broader sense of optimism among investors. In this environment, identifying undervalued stocks can be particularly appealing for investors seeking opportunities that may benefit from improving market sentiment and economic conditions.
OM:NREST
OM:NRESTHospitality

Exploring Three European Undiscovered Gems with Promising Potential

As European markets show resilience with the STOXX Europe 600 Index rising by 1.91% amid geopolitical developments and economic forecasts, investors are increasingly attentive to small-cap opportunities that might benefit from these broader trends. In this context, identifying stocks with strong fundamentals and growth potential becomes crucial for navigating the evolving landscape, particularly those that can capitalize on regional industrial production gains and stable monetary policy...
OM:EQT
OM:EQTCapital Markets

EQT Chair Handover To Jean Eric Salata Puts Global Growth In Focus

EQT AB (OM:EQT) has nominated Jean Eric Salata as the next Chairperson of the Board. Salata is set to succeed current Chairperson Conni Jonsson. The nomination signals an upcoming leadership transition at the top of EQT's governance structure. EQT AB, listed as OM:EQT, operates as an investment manager with a focus on private markets and fund management. A change in the chairperson role sits at the core of how the board oversees capital allocation, risk, and long term priorities, so many...
OM:MYCR
OM:MYCRElectronic

Mycronic (OM:MYCR) Valuation Check After Securing New US$27m–US$30m SLX Mask Writer Order

Mycronic (OM:MYCR) is back in focus after announcing a customized SLX laser mask writer order from a new customer, valued between US$27 million and US$30 million, with delivery planned for 2028. See our latest analysis for Mycronic. The SLX mask writer order comes at a time when momentum in Mycronic’s shares is clearly building, with a 27.5% 1 month share price return and a 47.46% 1 year total shareholder return. If this kind of semiconductor exposure interests you, it could be worth widening...
OM:DYVOX
OM:DYVOXTech

A Look At Dynavox Group (OM:DYVOX) Valuation As Growth Expectations Lift Investor Interest

Dynavox Group (OM:DYVOX) is back on investor radar after recent commentary highlighted the stock as undervalued relative to estimated future cash flows, with earnings and revenue growth expectations reported as above the Swedish market. See our latest analysis for Dynavox Group. Recent gains have been strong, with a 1 day share price return of 6.37% and a 30 day share price return of 24.72%, while the 1 year total shareholder return of 77.98% and 3 year total shareholder return of about 2.7x...
OM:HUSQ B
OM:HUSQ BMachinery

Assessing Husqvarna (OM:HUSQ B) Valuation After AGM Dividend Decision And Board Change

Dividend decision and board change set the tone for Husqvarna Husqvarna (OM:HUSQ B) is back on investors’ radars after its AGM approved a SEK 1.25 per share dividend for 2025 in two installments and confirmed Glen Instone as a new Board member. See our latest analysis for Husqvarna. The stock’s recent AGM news has followed a period of mixed price momentum, with a 30 day share price return of 18.75% contrasting with a year to date share price return of 10.37% and a 5 year total shareholder...
OM:GETI B
OM:GETI BMedical Equipment

Assessing Getinge (OM:GETI B) Valuation After Recent Share Price Rebound

What the recent performance in Getinge (OM:GETI B) signals for investors Getinge (OM:GETI B) has drawn fresh attention after a recent share move, with the stock up about 6% over the past week and around 13% over the past month. That short term shift sits against a year to date return of about 6% decline and a past 3 months return close to 3% decline, giving investors a mixed picture of recent momentum. See our latest analysis for Getinge. At a share price of SEK203.9, the recent 1 month share...
OM:SOBI
OM:SOBIBiotechs

Does Health Canada’s EMPAVELI Approval in C3G and IC-MPGN Change The Bull Case For Sobi (OM:SOBI)?

Swedish Orphan Biovitrum (Sobi) and partner Apellis Pharmaceuticals have received Health Canada approval for EMPAVELI (pegcetacoplan) to treat rare kidney diseases C3 glomerulopathy and primary IC-MPGN in patients aged 12 and older, based on Phase 3 VALIANT data showing reduced proteinuria, stabilized kidney function, and clearance of C3 deposits. This decision extends EMPAVELI’s nephrology footprint beyond the US and EU into Canada, adding another rare-disease indication to Sobi’s portfolio...